| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
49,160,000 |
| Market
Cap: |
172.06(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.61 - $9.85 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 3.3 |
| Insider 3/6 Months : 3.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,000 |
1,000 |
1,300 |
| Total Buy Value |
$0 |
$5,785 |
$5,785 |
$6,648 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
2 |
| Total Shares Sold |
0 |
0 |
16,011 |
16,011 |
| Total Sell Value |
$0 |
$0 |
$110,547 |
$110,547 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sohn Catherine A. |
Director |
– • – |
2025-03-17 |
4 |
B |
$5.78 |
$5,785 |
D/D |
1,000 |
1,000 |
2.39 |
-41% |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2025-03-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
67,787 |
14,069 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2025-02-02 |
4 |
D |
$6.64 |
$15,378 |
D/D |
(2,316) |
73,220 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2025-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,775 |
75,536 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2025-02-02 |
4 |
D |
$6.64 |
$54,992 |
D/D |
(8,282) |
355,082 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2025-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,950 |
363,364 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2025-02-02 |
4 |
D |
$6.64 |
$17,981 |
D/D |
(2,708) |
81,856 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2025-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,775 |
84,564 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2025-02-01 |
4 |
D |
$6.64 |
$11,959 |
D/D |
(1,801) |
67,761 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2025-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,166 |
69,562 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2025-02-01 |
4 |
D |
$6.64 |
$48,014 |
D/D |
(7,231) |
344,414 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2025-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,545 |
351,645 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2025-02-01 |
4 |
D |
$6.64 |
$14,004 |
D/D |
(2,109) |
76,789 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2025-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,166 |
78,898 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2025-01-31 |
4 |
A |
$5.18 |
$16,493 |
D/D |
3,184 |
63,396 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2025-01-31 |
4 |
A |
$5.18 |
$21,264 |
D/D |
4,105 |
335,100 |
|
- |
|
| Jordt Raymond M |
Chief Business Officer |
• – – |
2025-01-31 |
4 |
A |
$5.18 |
$13,541 |
D/D |
2,614 |
34,902 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2025-01-31 |
4 |
A |
$5.18 |
$9,868 |
D/D |
1,905 |
72,732 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2025-01-30 |
4 |
D |
$7.00 |
$18,963 |
D/D |
(2,709) |
60,212 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2025-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,275 |
62,921 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2025-01-30 |
4 |
D |
$7.00 |
$81,907 |
D/D |
(11,701) |
330,995 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2025-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,775 |
342,696 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2025-01-30 |
4 |
D |
$7.00 |
$22,211 |
D/D |
(3,173) |
70,827 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2025-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,275 |
74,000 |
|
- |
|
| Jordt Raymond M |
Chief Business Officer |
• – – |
2025-01-25 |
4 |
D |
$6.98 |
$26,957 |
D/D |
(3,862) |
32,288 |
|
- |
|
292 Records found
|
|
Page 1 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.11 (3.05%) 
